Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street's expectations, but shares fell hard in after-hours trading, in an echo of ...

Hims & Hers (HIMS) stock tumbled 20% post-market after the company released its Q4 earnings report and 2025 guidance amid a ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

Besides Mankind, Natco Pharma, Dr Reddy’s, Sun Pharma and others are already gearing up for launches of weight-loss drugs ...

Jonathan Van Ness is “so proud” of themself after losing 66 lbs. The Queer Eye star, 37, took to their Instagram Story on Sunday, Feb. 23 to share a before and after shot of their recent weight loss ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...

It’s hard to watch television without seeing advertisements for compounded GLP-1 weight-loss drugs cheaper than the authentic ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

We speak to Kerry North America CEO John Cahalane to find out more about the company’s renewed strategy at a time when consumer focus on health and nutrition is reaching a new high ...